Immunome Inc Stock Price, News & Analysis

Immunome, Inc. (NASDAQ: IMNM) has announced that its President and CEO, Purnanand Sarma, PhD, will present at the Jefferies Healthcare Conference on June 9 at 2:30 p.m. ET. The event will be accessible via a live audio webcast on the company's website, with a replay available for 90 days post-event. Immunome focuses on developing first-in-class antibody therapeutics using its human memory B cell platform, targeting oncology and infectious diseases, including COVID-19. For more details, visit www.immunome.com.

Immunome, Inc. (Nasdaq: IMNM) announced significant advancements in its lead oncology program, IMM-ONC-01, a novel therapy targeting the immunosuppressive cytokine IL-38. Preclinical research shows high mRNA expression of IL-38 in over 60 cancer sub-types, particularly in high unmet need cancers like Gastroesophageal and Head and Neck Squamous Carcinomas. Immunome collaborates with Fox Chase Cancer Center to confirm IL-38 protein expression in patients. The company plans to file an IND in 2H 2022 to expedite clinical development.

Immunome, Inc. (Nasdaq: IMNM) announced promising results from its COVID-19 antibody cocktail, IMM-BCP-01, which effectively neutralized the Omicron variant in in vivo studies with hamsters. The antibody IMM20253 also showed effectiveness against the BA.2 subvariant in in vitro tests. The research indicates that the cocktail retains substantial activity against various Omicron subvariants, enhancing confidence in their Phase 1b study. The study is supported by the U.S. Department of Defense.

Immunome, Inc. (Nasdaq: IMNM) reported its Q1 2022 financial results, highlighting FDA clearance for its Phase 1b clinical trial of the COVID-19 antibody cocktail, IMM-BCP-01. This therapy aims to address the urgent need for effective COVID-19 treatments amid new variants. The company also progresses its IL-38 targeting antibody treatment, IMM-ONC-01, with an IND submission planned for late 2022. Financially, R&D expenses were $8.1 million, G&A expenses were $3.6 million, and a net loss of $11.7 million was recorded. Cash reserves stood at $42.9 million as of March 31, 2022.

Immunome, Inc. (Nasdaq: IMNM) has received a safe-to-proceed notification from the U.S. FDA for its IMM-BCP-01 investigational new drug application, allowing progress towards a Phase 1b clinical trial. The company’s antibody cocktail has shown promising in vitro efficacy against the Omicron variant of COVID-19, neutralizing it with significantly higher potency than existing treatments. Financially, Immunome reported a net loss of $7.9M for Q4 2021, with cash reserves of $49.2M as of December 31, 2021. Ongoing projects include the development of IMM-ONC-01 for targeting IL-38 in oncology.

Immunome, Inc. (NASDAQ: IMNM) has announced that the FDA has lifted the clinical hold on its Investigational New Drug (IND) application for the antibody cocktail IMM-BCP-01, aimed at treating COVID-19. The hold was previously placed due to requests for additional information regarding the drug's preparation and administration. Immunome provided a comprehensive report to address these concerns. The company plans to initiate a placebo-controlled dose escalation study for IMM-BCP-01, which utilizes a three-antibody cocktail targeting the SARS-CoV-2 Spike protein.

Immunome (NASDAQ: IMNM) announced positive in vitro results for its antibody cocktail against the SARS-CoV-2 Omicron variant, demonstrating comparable potency to GSK/Vir's sotrovimab. The tests conducted at Boston University and Washington University confirmed that the combination of IMM20253 and IMM20184 neutralized Omicron with an IC50 of 27 nM. The cocktail employs a novel mechanism that enhances viral resistance, targeting the spike protein's ACE2 binding site. Moving forward, Immunome plans to advance its program into Phase 1b trials, supported by funding from the U.S. Department of Defense.

Immunome has received a clinical hold letter from the FDA regarding its IND submission for IMM-BCP-01, a three-antibody cocktail for COVID-19. The FDA has requested additional information about the cocktail's preparation and administration at clinical sites. Immunome intends to provide this information promptly and is still on track to report top-line clinical data for IMM-BCP-01 within the first half of 2022. Additionally, external laboratory tests for the cocktail's efficacy against the Omicron variant are expected this month.

Immunome, Inc. (Nasdaq: IMNM) will participate in a fireside chat hosted by Cantor Fitzgerald's Brian Cheng on December 8, 2021, at 1:00 p.m. ET, aimed at institutional clients. The event will be accessible via webcast, with a replay available on Immunome's website for 30 days following the live presentation.

Immunome utilizes its proprietary human memory B cell platform to develop innovative antibody therapeutics focusing on oncology and infectious diseases, including COVID-19.